Monoclonal antibody directed against DNGR-1 marker for CD8+ dendritic cells, which can be exploited for tumour therapy, whilst also recognising necrotic cells.
| Inventor | Institute |
|---|---|
| Caetano Reis e Sousa | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151705 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology;Stem cell biology |
| Application: | FACS ; IF ; WB |
| Target: | Mouse DNGR1 |
| Reactivity: | Mouse |
| Clone: | 1F6 |
| Host: | Rat |
| Class: | Monoclonal |
| Alternate name: | C-Type Lectin Domain Family 9 Member A; HEEE9341; UNQ9341; DNGR-1; CD37; DNGR1 |
|---|---|
| Product description: | Monoclonal antibody directed against DNGR-1 marker for CD8+ dendritic cells, which can be exploited for tumour therapy, whilst also recognising necrotic cells. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | RBL-2H3 cells expressing mouse DNGR-1 fused to an HA epitope |
| Immunogen Uniprot ID: | Q8BRU4 |
| Myeloma used: | Y3.AG.1.2.3 |
| Target background: | This antibody recognises mouse DNGR-1, also known as CLEC9A, which is a highly specific marker of the CD8a+ and the CD103+ DC subsets, as well as a receptor able to recognise a preformed signal exposed on necrotic cells. DNGR-1 was found to be expressed in mice at high levels by CD8+ DCs and at low levels by plasmacytoid DCs, but not by other hematopoietic cells. DNGR-1 is a novel, highly specific marker of mouse and human DC subsets that can be exploited for CTL cross-priming and tumour therapy. DNGR-1 ligation is required for effective cross-presentation of dead-cell-associated antigen by recruitment and activation of the tyrosine kinase Syk. DNGR-1 recognizes filamentous actin in association with particular actin-binding domains of cytoskeletal proteins, including spectrin, exposed when cell membranes are damaged. This antibody can recognise both the short and long isoform of DNGR-1, which vary in a segment of the stalk region. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Sancho et al. 2008. J Clin Invest. 118(6):2098-110. PMID: 18497879. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.